Literature DB >> 8301126

Analysis of mutant HLA-A2 molecules. Differential effects on peptide binding and CTL recognition.

L G Tussey1, M Matsui, S Rowland-Jones, R Warburton, J A Frelinger, A McMichael.   

Abstract

Previous studies have identified several residues lining the groove of the HLA-A2.1 molecule that are critical for Ag presentation. However, it is not clear whether these residues are critical for binding of the peptide epitope per se or for determining the appropriate conformation of bound peptide. To distinguish between these possibilities, mutations at eight of these residues have been tested for their effects on the ability of the molecule to bind and present two known peptide epitopes--one derived from the influenza A matrix protein, the other from HIV pol. With only one exception, the mutations were found to affect the binding of the two peptides similarly. Most of the mutations resulted in intermediate deleterious effects on binding, with the B pocket mutant F9Y having the most dramatic negative effect on binding for both peptides. Two of the mutations significantly enhanced binding of both peptides and a peptide-specific effect on binding was seen with the substitution, Y99H, which enhanced binding of the matrix peptide yet diminished binding of the pol peptide. In contrast to the effects on binding, the effects of the mutations on presentation differed considerably for the two peptides. The most striking difference was seen with two alpha 2 alpha helix mutants that are fully recognized by pol peptide-specific CTL but not recognized by matrix peptide-specific CTL even though levels of binding were comparably diminished for the two peptides. These results suggest that some interactions, although not critical for binding per se, are critical for functional binding and the importance of these interactions differs among peptide epitopes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8301126

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  A biochemical and structural analysis of genetic diversity within the HLA-A*11 subtype.

Authors:  Lenong Li; Weifeng Chen; Marlene Bouvier
Journal:  Immunogenetics       Date:  2005-05-04       Impact factor: 2.846

2.  Identification and functional perspective of a novel HLA-A allele: A*0279.

Authors:  Fangfang Liu; Shan Wang; Yingjiang Ye; Huagang Zhang; Yu Zhang; Weifeng Chen
Journal:  Immunogenetics       Date:  2006-04-01       Impact factor: 2.846

3.  Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality.

Authors:  Joseph Pidala; Tao Wang; Michael Haagenson; Stephen R Spellman; Medhat Askar; Minoo Battiwalla; Lee Ann Baxter-Lowe; Menachem Bitan; Marcelo Fernandez-Viña; Manish Gandhi; Ann A Jakubowski; Martin Maiers; Susana R Marino; Steven G E Marsh; Machteld Oudshoorn; Jeanne Palmer; Vinod K Prasad; Vijay Reddy; Olle Ringden; Wael Saber; Stella Santarone; Kirk R Schultz; Michelle Setterholm; Elizabeth Trachtenberg; E Victoria Turner; Ann E Woolfrey; Stephanie J Lee; Claudio Anasetti
Journal:  Blood       Date:  2013-08-27       Impact factor: 22.113

4.  Amino-terminal alteration of the HLA-A*0201-restricted human immunodeficiency virus pol peptide increases complex stability and in vitro immunogenicity.

Authors:  R R Pogue; J Eron; J A Frelinger; M Matsui
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-29       Impact factor: 11.205

5.  Identification of amino acids involved in recognition by dengue virus NS3-specific, HLA-DR15-restricted cytotoxic CD4+ T-cell clones.

Authors:  L Zeng; I Kurane; Y Okamoto; F A Ennis; M A Brinton
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

6.  Restoration of CTL recognition of a mutant FMP peptide by a compensatory change in HLA-A2.

Authors:  M Matsui; J A Frelinger
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

7.  Patients with chronic hepatitis C have circulating cytotoxic T cells which recognize hepatitis C virus-encoded peptides binding to HLA-A2.1 molecules.

Authors:  M Battegay; J Fikes; A M Di Bisceglie; P A Wentworth; A Sette; E Celis; W M Ching; A Grakoui; C M Rice; K Kurokohchi
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

8.  HLA-A2 subtypes are functionally distinct in peptide binding and presentation.

Authors:  D Barouch; T Friede; S Stevanović; L Tussey; K Smith; S Rowland-Jones; V Braud; A McMichael; H G Rammensee
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

9.  A naturally selected dimorphism within the HLA-B44 supertype alters class I structure, peptide repertoire, and T cell recognition.

Authors:  Whitney A Macdonald; Anthony W Purcell; Nicole A Mifsud; Lauren K Ely; David S Williams; Linus Chang; Jeffrey J Gorman; Craig S Clements; Lars Kjer-Nielsen; David M Koelle; Scott R Burrows; Brian D Tait; Rhonda Holdsworth; Andrew G Brooks; George O Lovrecz; Louis Lu; Jamie Rossjohn; James McCluskey
Journal:  J Exp Med       Date:  2003-08-25       Impact factor: 14.307

10.  A single nine-amino acid peptide induces virus-specific, CD8+ human cytotoxic T lymphocyte clones of heterogeneous serotype specificities.

Authors:  J Zivny; I Kurane; A M Leporati; M Ibe; M Takiguchi; L L Zeng; M A Brinton; F A Ennis
Journal:  J Exp Med       Date:  1995-09-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.